Clinical trials located in

Créteil

Créteil city is located in France. Currently, 20 clinical trials are being conducted in this city.

Créteil, a French city located in the southeastern suburbs of Paris, is the capital of the Val-de-Marne department. Established on the banks of the Marne River, it has a rich history dating back to the Gallo-Roman era. Notably, Créteil features a distinctive modernist architecture, exemplified by its prefabricated tower blocks from the 1960s. The city is also home to the Créteil Soleil, one of the largest shopping malls in the region. Additionally, Créteil is recognized for its vibrant cultural scene, including the Maison des Arts, a hub for contemporary arts.

  • CT-EU-00121077

    Study on the effectiveness and safety of DMX-200 for FSGS patients using ARB

    Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disease where some parts of the kidneys become scarred, leading to kidney damage and protein loss in urine. This study involves a therapy using an experimental drug named DMX-200 (also known as repagermanium), which, when taken with a type of medication called an Angiotensin II Receptor Blocker (ARB), aims to halt the inflammation that contributes to chronic kidney disease.

    The study is designed to assess how well DMX-200 works and how safe it is in treating people with FSGS. It will compare the effects of DMX-200 with a placebo over a period of 104 weeks (about 2 years). Patients will be given either DMX-200 in capsule form to take twice daily or a placebo. Given the rarity of FSGS, the study will include both adults and adolescents aged 12 to 17 years.

    The study will start with a screening period to ensure all necessary assessments are completed. This will be followed by the main treatment phase, lasting 104 weeks. After this, there will be a 4-week follow-up period without treatment to observe any changes. Patients who complete this double-blind period and might benefit from continued treatment will enter an open-label extension phase. During this phase, participants will receive DMX-200 for an additional 2 years, also followed by a 4-week off-treatment period for further observation.

    The goal is to determine the effectiveness and long-term safety of DMX-200 for treating FSGS. The study aims to improve understanding and develop new treatments for this challenging kidney condition.

    • DMX-200
    • placebo
  • Study on the effectiveness and safety of Ianalumab for treating Warm Autoimmune Hemolytic Anemia

    This clinical trial is designed to evaluate the efficacy and safety of a drug called ianalumab in patients with warm autoimmune hemolytic anemia (wAIHA) who have not responded to at least one previous treatment. The study aims to determine if ianalumab can induce and maintain a durable hemoglobin response compared to a placebo.

    Participants will be randomly assigned to receive one of two different doses of ianalumab or a placebo. If a participant assigned to the placebo group does not respond to the treatment, they may be given ianalumab in an open-label manner, meaning both the participant and the doctor will know they are receiving the drug.

    The investigational treatment will be administered through an intravenous (i.v.) infusion. During the study, participants will have regular visits every other week during the treatment period and primary endpoint follow-up period. For safety monitoring, visits will occur monthly for the first 20 weeks after the last dose and then quarterly for up to two years. If a participant achieves a durable response, additional monthly visits for efficacy will continue for the first two years after the last dose, followed by quarterly visits until the loss of response or the end of the study, which could be up to 39 months after the last participant is randomized.

    The primary goal is to see if ianalumab can achieve a durable hemoglobin response, defined as a hemoglobin level of at least 10 g/dL and an increase of at least 2 g/dL from baseline for a period of at least eight consecutive weeks between weeks 9 and 25, without the need for rescue medication or prohibited treatment.

    This study offers hope for patients with wAIHA who have not found success with other treatments, providing a potential new option to manage their condition.

    • placebo
  • Study WVE-003 in patients with early-stage Huntington’s disease

    This clinical trial is a study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a new drug called WVE-003 in adult patients with early Huntington’s disease (HD). WVE-003 is a type of drug designed to target specific genetic sequences. In this case, it is targeting a single nucleotide polymorphism (SNP), known as SNP3, in Huntington’s disease patients. The drug is administered intrathecally, i.e., it is injected into the spinal canal.

    The study is double-blind, meaning neither patients nor researchers know who is receiving the actual drug and who is receiving the placebo. This helps ensure the results are impartial. The primary goal is to evaluate the safety of WVE-003 by monitoring the percentage of patients who experienced adverse events from day 1 to the end of the study, which lasts a minimum of 36 weeks.

    • WVE-003
  • Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    • placebo
    • Fianlimab
    • Cemiplimab
    • Pembrolizumab
  • Studying rilzabrutinib for chronic immune thrombocytopenia

    The research is underway to evaluate the efficacy and safety of a medication called rilzabrutinib in adults and teenagers with Immune Thrombocytopenia (ITP), a chronic blood condition characterized by a low platelet count. Participants will receive either the medication or a placebo twice daily over a period of about a year and a half. Platelet levels, overall health, and quality of life will be measured before and during the study to gather comprehensive data.

    • Rilzabrutinib
  • Examining capivasertib and docetaxel in advanced prostate cancer

    This trial is testing a new potential treatment for a type of advanced prostate cancer. The study will compare two combinations: one with Capivasertib and another called Docetaxel, compared with placebo (a dummy tablet with no medical effect) and Docetaxel. In addition, each study participant will receive steroid treatment and another therapy called androgen deprivation therapy. The main goal of this study is to demonstrate whether Capivasertib + Docetaxel extends patients’ lives more than placebo + Docetaxel. They will also be monitored for the time it takes for the cancer to show signs of growth again, for the pain to increase or for urinary symptoms to worsen.

    • Capivasertib
    • Docetaxel
  • Glofitamab and obinutuzumab: new treatment study for Non-Hodgkin’s lymphoma

    In this study, researchers are trying to learn more about a new drug treatment for B-cell Non-Hodgkin’s Lymphoma – a type of blood cancer. The study is happening in many places and is open for patients who have not had success with their previous treatments. The new drug, called glofitamab, will be given to these patients. The amount of glofitamab will be slowly raised to ensure it’s safe. Another drug, obinutuzumab, will be used with glofitamab. The study will go in 3 steps. For the first two steps, the quantity of glofitamab will be increased slowly. When the safest large dose is found, this medicine will be given to more people in the last step.

    • Tocilizumab
    • Obinutuzumab
    • Glofitamab
  • Ceralasertib & durvalumab vs docetaxel in advanced lung cancer study

    This is an open-label study titled LATIFY, which means everyone will know the type of treatment they are receiving. The study team is looking into a specific type of lung cancer, called Non-Small Cell Lung Cancer (NSCLC) which did not get better after previous treatments. Two treatments will be tested, a new combination of ceralasertib plus durvalumab, compared to a commonly used treatment, docetaxel. Doctors will track participants’ health over time to see which treatment helps people live longer. Understanding the results will help doctors responsibly give the best treatment for patients with this type of lung cancer.

    • Ceralasertib
    • Durvalumab
    • Docetaxel
  • Testing golcadomide for safety & effectiveness in non-Hodgkin lymphomas

    This trial is about testing the safety and effectiveness of a drug called Golcadomide for people with a certain type of cancer called Non-Hodgkin Lymphomas that has come back or not responded to treatment. This drug can be taken by mouth and will be tested alone or together with other drugs used to treat lymphoma. It is for patients who tried at least two other treatments for their cancer, or if there arent suitable treatment for them. First, different doses of Golcadomide will be given to see which amount can be tolerated without causing too many side effects. Once that’s figured out, the trial will look at how well the chosen dose works either alone or with other lymphoma drugs. The researchersa will also study if eating food together with the drug will affect how the drug works and its safety.

    • Golcadomide/CC-99282
    • Valemetostat
    • Tafasitamab
    • Obinutuzumab
    • Rituximab
  • A clinical trial evaluating Tominersen in the treatment of early stages of Huntington’s disease

    This clinical trial is focused on evaluating the investigational drug, tominersen, in people in the early stages of Huntington’s disease, a genetic disorder characterized by the progressive loss of nerve cells in the brain.

    The aim of this study is to understand the potential of tominersen to slow the progression of the disease and improve quality of life by administering different doses of this drug or a placebo directly into the spinal cord to reach the areas of the brain most affected by the disease. Participants’ health will be closely monitored and a series of assessments will be conducted to track changes in motor function, cognitive abilities and emotional well-being. Additionally, the study will measure specific biomarkers to assess the biological impact of treatment, offering valuable information for tailoring future therapies. This study provides an important opportunity to better understand Huntington’s disease and explore effective treatment options.

    • Placebo
    • Tominersen
  • Studying riliprubart’s effect on the prevention and treatment of antibody-mediated rejection

    The aim of this study is to test a new drug called Riliprubart (BIVV020) to see if it can help address a common problem in kidney transplant patients called antibody-mediated rejection (AMR). AMR happens when the body fights against the new kidney. The study consists of two parts: group one tests whether Riliprubart can prevent the development of antimicrobial resistance, while group B tests whether it can help if antimicrobial resistance already exists. The test also checks whether the drug is safe, how it works in the body and whether the body perceives it as something foreign. The study lasts about 2 years, during which doctors carefully monitor the condition of the patients’ kidneys, possible side effects and how the drug moves through the body after administration.

    • Riliprubart
    • Immunoglobulin (IVIg)
    • Antithymocyte globulin
    • Mycophenolate
    • Rituximab
    • Corticosteroids
    • Tacrolimus
  • Continuing sickle cell treatment with crizanlizumab

    This study is for people with Sickle Cell Disease who have already been part of an earlier Novartis study about a medicine called crizanlizumab. After signing up, patients can get the medicine as soon as possible, following the same schedule as in the last study. Patients will be checked on 105 days after their last dose for their safety, unless they keep getting the medicine afterward. They plan to keep the study going for 10 years, or until the medicine is available to buy and is covered by health insurance. The aim is to let people who found the earlier study helpful have continued access to this medicine if they can’t get it otherwise. The researchers will also be recording any side effects people have while on this medicine.

    • Crizanlizumab
  • Testing new medicine for children’s migraine relief

    This study is a test to see how safe and effective a medicine called Atogepant is when given to children and teenagers (6 to 17 years old) who get migraines. Migraines are bad headaches that can make feel sick or sensitive to light and sound. Atogepant is a tablet that is already approved for adults who get migraines, and now the researchers want to see how it works for younger people. The patients will be divided into six groups, which will be given either a placebo, a low-dose Atogepant, or a high-dose Atogepant. This will continue for 12 weeks. After this, there may be further follow-up visits or another study where the patients can continue to take the Atogepant. Testing during the study will include doctor’s visits, blood tests, questionnaires and checking for any side effects.

    • Atogepant
  • Comparing the effectiveness of two treatments for severe nasal polyps and asthma

    This study is looking at two medications, called Dupilumab and Omalizumab, to see how well they work in people who have severe nose and sinus problems alongside asthma. The main goal is to see if Dupilumab is better at shrinking nasal polyps (small growths in the nose) and improving the sense of smell. Other goals include seeing if Dupilumab can improve symptoms, lung function, and overall health-related quality of life better than Omalizumab. The study also aims to understand how these drugs affect the severity of the disease and asthma control, and their safety. To assess all these, doctors will use various tests, like measuring the size of nasal polyps, testing the ability to smell, and how well one’s lungs are working. Participants in the study will be involved for 38 weeks.

    • Dupilumab
    • Omalizumab
  • Comparing treatments in multiple myeloma: talquetamab in combination with other medication

    This study aims to explore the combined effects of talquetamab, daratumumab, pomalidomide, and dexamethasone for treating relapsed or refractory multiple myeloma. One group of patients will receive talquetamab subcutaneous in combination with daratumumab and pomalidomide. The second group will receive talquetamab subcutaneous in combination with daratumumab. The patients of the third group will be treated with daratumumab subcutaneous in combination with pomalidomide and dexamethasone. The research is divided into three phases: screening, treatment, and post-treatment follow-up. The study will assess efficacy, safety, and monitoring various health indicators at specific time points. The results of this combination therapy will be compared to choose the safest and the most effective treatment. The overall duration of the study is expected to be up to 6 years and 6 months.

    • Pomalidomide
    • Talquetamab
    • Dexamethasone
    • Daratumumab
  • Long-term safety evaluation of luspatercept treatment

    The study focuses on patients with myeloproliferative neoplasms. It tests the drug Luspatercept (ACE-536), evaluating its safety and efficacy over a long term compared to a placebo. This study assessing the prolonged safety of luspatercept in individuals previously enrolled in luspatercept studies. The trial involves multiple phases, including an initial assessment and a follow-up period, where the effects of Luspatercept on the disease’s progression and symptoms are closely monitored. This helps determine if the drug can significantly improve the condition or quality of life for those affected by these neoplasms.

    • Luspatercept
  • Monitoring the long-term safety of Nivolumab for cancer survivors

    This study is designed to understand the long-term effects of a medicine called Nivolumab in patients who have fought against various forms of cancer. In this study, the focus is on closely examining the long-term efficiency and safety of Nivolumab. Participants in the investigation encompass both current and past users of Nivolumab.

    • Nivolumab
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    • Milvexian
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil

See more clinical trials in other cities in France:

.